Objective:To investigate the effect of peroxisome proliferator activated receptors-γ(PPAR-γ) agonist Rosiglitazone on the immune maturation of monocyte-derived dendritic cell(DC) induced by advanced glycosylation end products(AGEs). Methods:Monocytes were purified(over 98%) using Anti-CD14 microbeads. After cultured with DC Cellgro medium containing recombinated human granulocyte-macrophage colony stimulating factor(rhGM-CSF)(100 μg/L) and recombinated human interleukin-4(rhIL-4)(20 μg/L) for 5 days,monocytes were derived into immature DC. Rosiglitazone(50 μmol/L) was added to the medium for 24 hours. The advanced glycosylation end-human serum albumin(AGE-HSA)(200 μg/ml) was then added to the medium for another 48 hours. The expressions of(CD1a,CD80,CD86 and HLA-DR) were analyzed by FACS,and the cytokines secretions of culture supernatants(IL-10,IL-12,TNF-α and INF-γ) were measured by ELISA. Results:Rosiglitazone reduced AGE-HSA inducing expressions of CD1a,CD80,CD86 and HLA-DR,and also inhibited AGE-HSA inducing T-cell stimulatory activity. The cytokines secretions of DCs induced by AGE-HSA were significantly attenuated by Rosiglitazone. Conclusion:The study suggested that one of the anti-inflammatory mechanisms of PPAR-γ agonist Rosiglitazone should be mediated by inhibiting the AGEs induced maturation and immune function of DCs.